Top Tech Companies in Raleigh, NC (1,113)

Resilient & Sustainable Growth: Revenue has increased year over year to a new high, with all three major service lines posting gains despite a slower pace. Growth remains uneven by region, but the overall trajectory is upward over the last several fiscal years.

Future-Ready Strategy: Multi‑billion‑dollar investments in technology—especially nearly $1.5B in AI—along with acquisitions and scaling managed services indicate a deliberate pivot to future growth levers. Leadership attention to next‑generation audit and AI‑enabled capabilities underscores preparation for emerging demand.

Strong Market Position & Advantage: The organization is characterized as a leading global professional‑services network with broad scale across assurance, advisory, and tax and repeated external recognitions in select consulting categories. Reach across major multinational clients supports durable competitive positioning.

Strong Revenue Growth: Revenue is rising at a double‑digit pace across 2025 and into 2026, with consistent year‑over‑year gains. Galleri test volumes and screening revenue also increased, signaling sustained commercial momentum.

Market Expansion: Access is broadening through major EHR integrations and a growing provider network, alongside initiatives to enter new geographies. These moves extend reach beyond core channels and support continued adoption.

Investor Backing & Capital Strength: Capital raises and a sizable cash position provide a multi‑year runway to fund commercialization, trials, and regulatory efforts. Strategic financings with prominent partners reinforce the ability to invest through scale‑up.

Strong Revenue Growth: Revenue increased from $698.4M in 2023 to $907.0M in 2025 (roughly 14% growth in both 2024 and 2025), with Q1–Q2 2026 up 15% and 13% year over year, respectively. Management guides to 10–13% revenue growth for 2026, indicating continued expansion.

Profitability: GAAP net income and adjusted EBITDA rose sharply in 2025 (+53% and +25%, respectively), and Q2 2026 adjusted EBITDA increased to $84.7M. Operating cash generation was solid in Q2 2026, reinforcing financial stability.

Market Expansion: The paying‑dealer base reached 34,629 in Q2 2026 (+5% YoY) with faster growth internationally (+11% vs. +3% in the U.S.). Monetization per dealer improved as Q2 2026 QARSD rose 7% year over year (U.S. +8%, International +11%).

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Strong Revenue Growth: Revenue is expanding rapidly, highlighted by 1,012% three-year growth and a No. 336 placement on the 2026 Inc. 5000, with management indicating revenue doubled in 2023 and 2024. External coverage further describes the company as in a “hyper-growth” phase.

Investor Backing & Capital Strength: Capital position is reinforced by a $127 million Series C in 2025 at a $1 billion valuation, with cumulative funding reported above $225 million. This provides substantial resources for continued scaling and product investment.

Market Expansion: The geographic footprint is widening with an East Coast headquarters in Raleigh and a Canadian headquarters in Toronto, while the customer base has expanded from around 1,000 to 1,500+ contractors across North America. These steps signal broader market reach and operating scale.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Strong Revenue Growth: Revenue has increased for multiple consecutive years, surpassing $3.0B in 2025 with continued growth into early 2026, including positive organic gains across all major segments. Filings indicate the trajectory is broad-based rather than acquisition-driven.

Profitability: Profitability is expanding faster than sales, with strong adjusted EBITDA growth and notable margin improvement in 2025. Subsequent quarterly updates show further gains, reinforcing operating leverage.

Healthy Cash Flow: Operating cash flow increased to roughly $600M in 2025, with stronger free cash flow supporting continued investment in labs and capacity expansion. This cash generation underpins ongoing growth initiatives.

Strong Revenue Growth: Revenue appears to be increasing over time, with evidence of substantial growth in 2022 and continued year-over-year expansion into early 2023, even as the pace moderates. Feedback suggests the business is still scaling toward a larger revenue base while transitioning to a mature growth profile.

Profitability: Independent credit commentary highlights improved profitability and a deliberate shift toward a profit-focused operating model. Feedback suggests efficiency gains and margin improvement are becoming central to the company’s stability and growth trajectory.

Innovation-Driven Growth: Ongoing AI platform investment, rising adoption of AI capabilities, and product expansion including acquisitions are cited as current growth engines. Feedback suggests these initiatives are supporting continued operational and market expansion.

Strong Market Position & Advantage: Market position is described as leading, with the largest customer base and highest revenue share among process‑mining vendors, and the highest share across major regions and buyer segments. Independent analyst assessments also continue to place the company among category leaders, pointing to durable advantage.

Innovation-Driven Growth: The company is expanding from core process mining into Process Intelligence and Enterprise AI, introducing offerings such as AgentC, AI agents, integrations, and an Orchestration Engine. Reported customer‑value milestones and ongoing platform updates suggest innovation is translating into adoption and impact.

Market Expansion: Enterprise deployments reportedly increased from more than 2,500 in 2022 to 5,000+ currently, with 1,400+ businesses served and 20+ offices. Regional traction includes progress such as capturing a majority of CAC 40 firms within five years in France.

Strong Revenue Growth: Reported doubling of revenue from 2019–2022 and back-to-back Inc. 5000 recognitions indicate sustained top-line momentum. Additional signals include a stated base of 1,000+ clients and active hiring language on the careers page.

Investor Backing & Capital Strength: In February 2025, the company secured a growth investment from Boathouse Capital explicitly to scale services, enter new markets, and pursue targeted acquisitions. This capital positions the firm to accelerate its next phase of growth.

Market Expansion: The company expanded its footprint via acquisitions, a larger Chicago headquarters, and international build‑out in Europe (e.g., Bulgaria/London). Leadership appointments in 2025–2026 were framed around entering new markets and scaling services.

Market Expansion: Office openings in Nashville and Raleigh and later international presence in Dublin and Lisbon signal an expanding footprint, with the Highspring platform citing 45+ offices worldwide. Leadership additions and ongoing regional build-outs under the unified brand indicate continued selective growth.

Future-Ready Strategy: The rebrand into Highspring unifies consulting, managed services, and talent solutions, positioning the business for cross-selling and integrated delivery. Portfolio sharpening—carving out cyber while focusing on finance/technology transformation and risk/controls—aligns capabilities for scalable execution.

Strategic Partnerships: Capabilities emphasize ERP/EPM ecosystems (e.g., NetSuite, SAP, Microsoft, OneStream) that underpin execution-led growth. Supply chain depth via Plantensive and recognition in the Blue Yonder ecosystem reinforce partner-led market access and delivery leverage.

Strong Revenue Growth: Revenue is rising at a double‑digit pace across recent quarters and the latest fiscal year, with momentum reflected in higher quarterly results and a raised full‑year outlook. Near‑term guidance also points to continued expansion through the remainder of the year.

Profitability: Profitability has expanded alongside growth, with operating income and earnings increasing meaningfully in the latest quarter. A subscription‑heavy mix and higher full‑year operating income guidance support margin durability.

Strong Market Position & Advantage: Position in life‑sciences CRM remains dominant, with a very large share of biopharma seats cited by management and many top‑20 pharmas live on next‑gen Vault CRM. Broad adoption across Development and Quality Clouds and continued big‑pharma commitments reinforce competitive advantage.